Bio-Rad Laboratories (BIO) Short term Debt (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Short term Debt data on file, last reported at $400.5 million in Q1 2026.

• On a quarterly basis, Short term Debt rose 33275.0% year-over-year to $400.5 million in Q1 2026; TTM through Mar 2026 was $400.5 million, a 33275.0% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 8.33% from the prior year.
• Short term Debt for Q1 2026 stood at $400.5 million, up from $1.3 million in the prior quarter.
• Over the last five years, Short term Debt for BIO reached as high as $400.5 million in Q1 2026 and fell as low as $448000.0 in Q3 2022.
• Historically, Short term Debt has averaged $24.3 million across 5 years, with a median of $504000.0 in 2022.
• Across the five-year window, Short term Debt plunged 74.24% in 2022 and surged 33275.0% in 2026, its largest moves.
• Year by year, Short term Debt stood at $465000.0 in 2022, then climbed by 7.53% to $500000.0 in 2023, then soared by 140.0% to $1.2 million in 2024, then increased by 8.33% to $1.3 million in 2025, then soared by 30707.69% to $400.5 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $400.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.